Literature DB >> 15389996

Salivary production in Parkinson's disease.

Melisa Proulx1, François P de Courval, Michael A Wiseman, Michel Panisset.   

Abstract

Hypersialorrhea is a common phenomenon in Parkinson disease (PD). The objective of this study was to determine whether patients with PD had an abnormally increased production of saliva and whether the production of saliva could be associated to factors related to either the disease characteristics or to its treatment. A total of 83 patients with PD and 55 control subjects participated in this study. Because of the age difference between the two groups, comparisons were made on a +/-2-year age-matched sample of 44 PD patients and 44 control subjects. PD patients produced significantly less saliva than control subjects. Correlations were obtained with the 83 PD patients between unstimulated salivary flow and patients characteristics. When controlling for age, sex, and Hoehn and Yahr scale, decreased production of saliva correlated significantly with the dose of levodopa and the symptoms of xerostomia. When controlling for medications, there was no relationship between the production of saliva and the evolution of the disease. This study shows that patients with PD produce less saliva than normal. Factors influencing the production of saliva include the use of levodopa and female gender. Our results may have implications for the treatment of drooling in PD. Copyright 2004 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15389996     DOI: 10.1002/mds.20189

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  35 in total

Review 1.  Gut dysfunction in Parkinson's disease.

Authors:  Adreesh Mukherjee; Atanu Biswas; Shyamal Kumar Das
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

2.  Impact of drooling in Parkinson's disease.

Authors:  Johanna G Kalf; Anne M Smit; Bastiaan R Bloem; Machiel J Zwarts; Marten Munneke
Journal:  J Neurol       Date:  2007-08-02       Impact factor: 4.849

3.  Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients.

Authors:  Maurits E L Arbouw; Kris L L Movig; Cees Neef; Henk-Jan Guchelaar; Toine C G Egberts
Journal:  Eur J Clin Pharmacol       Date:  2007-01-03       Impact factor: 2.953

Review 4.  Evidence for the effectiveness of botulinum toxin for sialorrhoea.

Authors:  D D Truong; R Bhidayasiri
Journal:  J Neural Transm (Vienna)       Date:  2008-02-04       Impact factor: 3.575

Review 5.  The option of sonographic guidance in Botulinum toxin injection for drooling in Parkinson's disease.

Authors:  Wolfgang H Jost
Journal:  J Neural Transm (Vienna)       Date:  2015-07-03       Impact factor: 3.575

Review 6.  Clinical features associated with drooling in Parkinson's disease.

Authors:  David Nascimento
Journal:  Neurol Sci       Date:  2021-01-14       Impact factor: 3.307

Review 7.  Drooling in Parkinson's disease: a review.

Authors:  Prachaya Srivanitchapoom; Sanjay Pandey; Mark Hallett
Journal:  Parkinsonism Relat Disord       Date:  2014-08-27       Impact factor: 4.891

8.  The use of botulinum toxin in the treatment of sialorrhea in parkinsonian disorders.

Authors:  María T Gómez-Caravaca; María T Cáceres-Redondo; Ismael Huertas-Fernández; Laura Vargas-González; Fátima Carrillo; Manuel Carballo; Pablo Mir
Journal:  Neurol Sci       Date:  2014-09-20       Impact factor: 3.307

9.  Visuomotor control of neck surface electromyography in Parkinson's disease.

Authors:  Jessica R Malloy; Juliana C Valentin; Gabrielle L Hands; Christina A Stevens; Susan E Langmore; J Pieter Noordzij; Cara E Stepp
Journal:  NeuroRehabilitation       Date:  2014       Impact factor: 2.138

10.  Speech and Swallowing in Parkinson's Disease.

Authors:  Kris Tjaden
Journal:  Top Geriatr Rehabil       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.